*Issuer Sponsored Content by Oncolytics Biotech, Inc
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Pelareorep: A First-in-Class dsRNA Immunotherapy with FDA Pivotal Alignment Delivering 3–4x Survival Gains in Multiple GI Cancers
ONCY has multiple FDA Fast Track Designations, clinical validation in 1,200+ patients
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
READ THE INVESTOR PRESENTATION HERE
_________________________
Hello Everyone,
Yesterday’s alert did not disappoint by any means. It opened at 16.54 before running to 20 later on in the session for a pretty impressive move to the upside. That was the 3rd time in a row that one demonstrated its ability to move double digits for us.
Moving on we have a different but unique situation for today’s session.
Not every $1.00 stock on the NASDAQ deserves a second look but ONCY might be one of the exceptions.
This one was sub .80 less than 2 weeks ago before it went on a 6 session green run that launched it all the way to 1.18. It was a monster move.
Just yesterday it pulled back below $1 and we think that this is a great time to research this one given the timing.
Could ONCY be ready for the next leg up after a healthy pull back with some expected profit taking?
The clinical-stage biotech behind pelareorep just secured FDA alignment on a pivotal registrational trial in metastatic anal cancer — a development that fundamentally changes the regulatory conversation around this company. Pair that with some of the more striking durability numbers seen in GI oncology recently, and ONCY is quietly building a case that’s harder to dismiss.
With multiple FDA Fast Track Designations, clinical validation in 1,200+ patients, and a registration-focused development strategy in colorectal and anal cancers, pelareorep is positioned as a differentiated immunotherapy platform targeting some of the largest and most underserved opportunities in oncology
The FDA Milestone That Changes the Math
In April 2026, Oncolytics reached alignment with the FDA on a registrational trial design for pelareorep in squamous cell anal cancer. This isn’t just a procedural checkbox — it’s a defined pathway toward potential approval.
The trial structure includes:
- A single randomized study capable of supporting both accelerated and full approval
- Pelareorep combined with a checkpoint inhibitor
- Second-line and beyond SCAC patients
- Approximately 80–100 participants
- Primary endpoints centered on objective response rate and duration of response
- Expected initiation in the second half of 2026
Late-stage anal cancer remains an area with no firmly established standard of care, which creates real space for a therapy producing durable responses.
The Colorectal Data That’s Getting Attention
The numbers coming out of ONCY’s colorectal cancer program are what initially put the company on the radar for many biotech watchers. In KRAS-mutant MSS metastatic colorectal cancer — historically one of the most resistant tumor types — pelareorep’s combination approach has posted results well above historical baselines:
- 19.5-month median duration of response — compared to a typical 4–6 months
- 33% response rate — versus a historical range of 6–11%
- 27-month median overall survival — more than double the usual 11–13 month benchmark
- 16.6-month progression-free survival — against a historical 5–7 month range
These aren’t marginal improvements. The durability gap between pelareorep’s data and standard-of-care history is wide enough to warrant serious attention.
Why the Platform Matters
The underlying science gives some context for why the data looks the way it does. Most GI tumors are immunologically “cold” — the immune system essentially fails to recognize them as threats, which is a core reason checkpoint inhibitors alone have underperformed in colorectal and pancreatic settings.
Pelareorep is an intravenously delivered dsRNA immunotherapy designed to work around that problem. It selectively replicates inside tumor cells, triggers immunogenic cell death, and appears to remodel the tumor microenvironment in ways that make checkpoint inhibitors more effective. The result is a potential “cold to hot” tumor conversion — activating both innate and adaptive immune responses in cancers that have historically resisted them.
CEO Jared Kelly has described the ambition as building pelareorep into a “backbone immunotherapy” across multiple cancer types, which is a bold framing — but the multi-indication data is at least beginning to support the thesis.
The Market Opportunity
The indications ONCY is targeting aren’t small. The global colorectal cancer therapeutics market is estimated around $20 billion, with the specific second-line KRAS-mutant MSS segment representing a potential $3–5 billion annual opportunity given how few effective options currently exist. Pancreatic cancer adds another multi-billion-dollar layer, and the anal cancer market is projected to expand significantly over the next decade.
For a company trading under a dollar, the gap between current valuation and addressable opportunity is notable.
What to Watch
Execution is the variable that matters most from here. The key milestones on the horizon include the anticipated trial launch in anal cancer, further data updates from the colorectal program, and any partnership or collaboration developments that could accelerate the pipeline.
ONCY carries the risk profile inherent to any clinical-stage biotech — regulatory outcomes are never certain, and early data doesn’t guarantee late-stage success. But the combination of FDA alignment, multi-indication durability data, Fast Track designations, and a sub-dollar entry point creates the kind of asymmetric setup that tends to attract attention in the small-cap biotech space.
The story is still being written. But the recent chapters have been more interesting than most.
Pipeline
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-tumor activity in combination than with the individual approaches alone. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.
Based on these findings, the Company is planning additional studies in models of pancreatic ductal adenocarcinoma (“PDAC”) and colorectal cancer (“CRC”) designed to further evaluate the combinations’ effects on immune activation, tumor response durability, and time-to-resistance. The ongoing work includes evaluations of pelareorep in combination with KRAS G12C inhibitors, pan-RAS inhibitors, and additional next-generation RAS pathway-targeting agents in RAS-mutated tumor models.
“We believe these initial findings further support pelareorep’s potential to serve as an immune-priming backbone for next-generation targeted therapies,” said Jared Kelly, Chief Executive Officer of Oncolytics. “RAS-mutated tumors, particularly pancreatic and colorectal cancers, remain among the most difficult cancers to treat due to intrinsic immune resistance and the emergence of therapeutic resistance over time. These preclinical results support further study of the combinations’ anti-tumor and immune effects, including in models designed to assess durability and time-to-resistance.”
Mr. Kelly continued, “Importantly, we believe this strategy may ultimately represent a potentially important area for further investigation in pancreatic cancer, where nearly all tumors harbor RAS pathway alterations and where patients continue to face extremely limited treatment options. The potential synergy observed in previous PDAC clinical studies and preclinical RAS-targeted modalities reinforces our belief that pelareorep may play an important role in future combination strategies designed to improve the durability of targeted therapies.”
Full results from the initial preclinical studies are expected to be presented in the fall or winter of 2026.
NEWS
3 days ago
May 22, 2026
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
May 4, 2026
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Apr 27, 2026
Apr 6, 2026
Oncolytics Biotech® Completes Domicile Change to the United States
Apr 1, 2026
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Mar 19, 2026
Mar 19, 2026
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Mar 5, 2026
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
Mar 2, 2026
MANAGEMENT
Jared Kelly
Chief Executive Officer & Director
Jared Kelly is an accomplished lawyer and executive with a distinguished career in corporate law, particularly within the biotechnology sector. Mr. Kelly recently served as head of legal and corporate strategy at Ambrx and played a central role in its $2 billion sale to Johnson & Johnson. He has managed numerous transactions in the biotech space for companies at various stages of development. After leaving Ambrx, he has served as an advisor to multiple public and private drug development and pharmaceutical companies. Prior to becoming a biotech executive, Mr. Kelly was a sought-after public company lawyer who began his career with Kirkland & Ellis LLP, where he represented various public companies in securities offerings, IPOs and merger transactions. He also served as a partner at Lowenstein Sandler LLP, where his practice focused on representing biotechnology companies in financing transactions, mergers and acquisitions, and other complex transactions. Mr. Kelly received his J.D. and an LL.M. in Securities and Financial Regulation from Georgetown University Law Center, where he was the recipient of multiple honors and fellowships, including the Lane Evans Fellowship and Decrane Scholarship.
Kirk Look, CA, MSJ
Chief Financial Officer
Kirk Look is a Chartered Accountant with more than twenty years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company’s Controller in April 2003 and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst & Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst & Young LLP in Chile. Mr. Look has a Bachelor of Commerce from the University of Calgary and a Master of Science in Jurisprudence Law Degree from the Seton Hall Law School.
Thomas C. Heineman, MD, PhD
Chief Medical Officer
Prior to joining Oncolytics, Dr. Thomas Heineman was Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, he served as Vice President and Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics. At Halozyme, Dr. Heineman was also Head of Translational Medicine and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman’s experience further extends to big pharma and academia, as he previously worked as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD and PhD in Virology at the University of Chicago.
Allison Hagerman, PEng, PMP, MBT
Chief Technology Officer
A professional engineer focused on biotechnology, Allison Hagerman joined Oncolytics in 2010 and has been integral to the progress of its product development program ever since. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013, during which time she led the process performance qualification for pelareorep drug substance. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences. She is an accomplished equestrian and spends her spare time on horseback.
SINCERELY,
DISCLAIMER
MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.
The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell. The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.
Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.
The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.
The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.
The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.
The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk. The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.
Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com to obtain information about the Issuers.
Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com and www.sec.gov.
The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:
▪ An independent advisor or consultant;
▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;
▪ Stock picker;
▪ Securities trading expert;
▪ Securities researcher or analyst;
▪ Financial planner or financial planning;
▪ Provider of stock recommendations;
▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or
▪ Making an offer or sale of securities or solicitation to purchase securities.
An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information. Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.
▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.
▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.
▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.
▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.
▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.
▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org. You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.
▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.
The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:
Name of Issuer: Oncolytics Biotech, Inc
Amount of Cash Compensation: twenty thousand usd
Period of Publication of Information: One day campaign beginning and ending on June third twenty twenty six
Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.
By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.